Pituitary neuroendocrine tumors (PitNETs), also known as pituitary adenomas, approximately affect 5-10% of the general population during their lifetime. Some tumors, even small ones, may overproduce several kinds of hormones. Excessive hormone secretion may cause Cushing’s disease, acromegaly, galactorrhea, hyperprolactinemia, reproductive problems and prolactinoma. The pathogenesis of most PitNETs is still poorly understood, less than 5% of PtiNETs confirmed pathogenetic mutations.
The goals of treatment are to restore normal hormone secretion, release compression, decrease regrowth rate and other complications such as central nervous system damage, visual loss, cerebrospinal fluid leakage, hypopituitarism, diabetes insipidus and even death. For most of the PtiNETs, transsphenoidal surgery is the initial treatment if medical therapy for patients failed. Irradiation is usually for patients with inadequate tumor resection, imbalance hormone levels or less response to medications.
This research topic aims to highlight the advances in exploring aspects of Pituitary neuroendocrine tumors (PitNETs) tumorigenesis, pathogenesis, diagnosis and novel therapeutic targets. We welcome manuscripts of original research articles, and comprehensive reviews that cover, but are not limited to, these topics:
- Detailed cellular and molecular mechanism of PitNETs tumorigenesis, development and pathogenesis.
- Related signaling pathways recruited in PitNETs tumorigenesis and pathogenesis.
- Tumor microenvironment and immune reaction.
- Identification of diagnosis markers of PitNETs.
- Potential for novel therapeutic targets or strategies of PitNETs .
- Preclinical models and clinical study designs.
Pituitary neuroendocrine tumors (PitNETs), also known as pituitary adenomas, approximately affect 5-10% of the general population during their lifetime. Some tumors, even small ones, may overproduce several kinds of hormones. Excessive hormone secretion may cause Cushing’s disease, acromegaly, galactorrhea, hyperprolactinemia, reproductive problems and prolactinoma. The pathogenesis of most PitNETs is still poorly understood, less than 5% of PtiNETs confirmed pathogenetic mutations.
The goals of treatment are to restore normal hormone secretion, release compression, decrease regrowth rate and other complications such as central nervous system damage, visual loss, cerebrospinal fluid leakage, hypopituitarism, diabetes insipidus and even death. For most of the PtiNETs, transsphenoidal surgery is the initial treatment if medical therapy for patients failed. Irradiation is usually for patients with inadequate tumor resection, imbalance hormone levels or less response to medications.
This research topic aims to highlight the advances in exploring aspects of Pituitary neuroendocrine tumors (PitNETs) tumorigenesis, pathogenesis, diagnosis and novel therapeutic targets. We welcome manuscripts of original research articles, and comprehensive reviews that cover, but are not limited to, these topics:
- Detailed cellular and molecular mechanism of PitNETs tumorigenesis, development and pathogenesis.
- Related signaling pathways recruited in PitNETs tumorigenesis and pathogenesis.
- Tumor microenvironment and immune reaction.
- Identification of diagnosis markers of PitNETs.
- Potential for novel therapeutic targets or strategies of PitNETs .
- Preclinical models and clinical study designs.